Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Yen

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Assay and Drug Development Technologies|May 21, 2010
A plate-based assay to measure cellular ERK substrate phosphorylation: utility for drug discovery of the MAPK-signaling cascadeSreemathy Ramaswamy, Ivana Yen, Steve Sideris, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1Lewis Gazzard, Brent Appleton, Kerry Chapman, et al.
Cancer Cell|August 27, 2014
Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signalingJacob R Haling, Jawahar Sudhamsu, Ivana Yen, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2015
4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinaseEmily J Hanan, Matt Baumgardner, Marian C Bryan, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Molecular Cancer Therapeutics|July 23, 2013
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900Elizabeth Blackwood, Jennifer Epler, Ivana Yen, et al.
Cell Chemical Biology|February 11, 2023
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradationScott C Rosenberg, Frances Shanahan, Sayumi Yamazoe, et al.
Cancer Cell|October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant TumorsIvana Yen, Frances Shanahan, Mark Merchant, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Cancer Cell|March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Assay and Drug Development Technologies|May 21, 2010
A plate-based assay to measure cellular ERK substrate phosphorylation: utility for drug discovery of the MAPK-signaling cascadeSreemathy Ramaswamy, Ivana Yen, Steve Sideris, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1Lewis Gazzard, Brent Appleton, Kerry Chapman, et al.
Cancer Cell|August 27, 2014
Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signalingJacob R Haling, Jawahar Sudhamsu, Ivana Yen, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2015
4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinaseEmily J Hanan, Matt Baumgardner, Marian C Bryan, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Molecular Cancer Therapeutics|July 23, 2013
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900Elizabeth Blackwood, Jennifer Epler, Ivana Yen, et al.
Cell Chemical Biology|February 11, 2023
Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradationScott C Rosenberg, Frances Shanahan, Sayumi Yamazoe, et al.
Cancer Cell|October 10, 2018
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant TumorsIvana Yen, Frances Shanahan, Mark Merchant, et al.
Bioorganic & Medicinal Chemistry Letters|September 10, 2013
Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenaseBenjamin P Fauber, Peter S Dragovich, Jinhua Chen, et al.
Cancer Cell|March 22, 2016
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Scott A Foster, Daniel M Whalen, Ayşegül Özen, et al.
Pageof 3